An analysis of data from the TREAT Registry found that babies born to women who continued to treat their Crohn’s disease with infliximab during pregnancy had outcomes similar to those who did not take the drug. “The majority of both maternal pregnancies and partner outcomes resulted in live births of healthy infants across exposure groups” researchers wrote. Neonatal complication rates were low, according to a study published in The American Journal of Gastroenterology.

See the article in the American Journal of Gastroenterology here.